ArticleeLife2019
A chemical probe of CARM1 alters epigenetic plasticity against breast cancer cell invasion.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in eLife, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 59 citations in OpenAlex.
- Targeting PRMTs with small-molecule inhibitors: a comprehensive review.RSC medicinal chemistry · 2026Review
- A suite of macrocyclic peptide inhibitors and substrate probes for arginine methyltransferases.Chemical science · 2026Article
- Protein arginine methyltransferases in cancer: mechanisms, functions, and therapeutic opportunities.Journal of biomedical science · 2026Review
- Utilizing the HiBiT System to Identify CARM1 Degraders for Targeted Cancer Therapy.Journal of medicinal chemistry · 2026Article
- Multifaceted roles of CARM1 beyond histone arginine methylation.Experimental & molecular medicine · 2025Review
- Structure-Guided Design of a KMT9 Inhibitor Prodrug with Cellular Activity.Journal of medicinal chemistry · 2025Article
- Design, synthesis and evaluation of pyrimidinobenzylamide and pyrimidinothiophenamide derivatives as inhibitors of DOT1L and related epigenetic targets DNMT3a, PRMT4 and other HMTs.RSC medicinal chemistry · 2025Article
- PRMT3 and CARM1: Emerging Epigenetic Targets in Cancer.Journal of cellular and molecular medicine · 2025Review
- The emerging role of CARM1 in cancer.Cellular oncology (Dordrecht, Netherlands) · 2024Review
- Protein Arginine Methyltransferase CARM1 in Human Breast Cancer.Endocrinology · 2024Review
- A CARM1 Inhibitor Potently Suppresses Breast Cancer Both In Vitro and In Vivo.Journal of medicinal chemistry · 2024Article
- Structure-guided design of a selective inhibitor of the methyltransferase KMT9 with cellular activity.Nature communications · 2024Article
- A unique binding pocket induced by a noncanonical SAH mimic to develop potent and selective PRMT inhibitors.Acta pharmaceutica Sinica. B · 2023Article
- Discovery and biological evaluation of novel CARM1/HDAC2 dual-targeting inhibitors with anti-prostate cancer agents.Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.Journal of medicinal chemistry · 2023Article
- Development of Potent and Selective Coactivator-Associated Arginine Methyltransferase 1 (CARM1) Degraders.Journal of medicinal chemistry · 2023Article
- The NFIB/CARM1 partnership is a driver in preclinical models of small cell lung cancer.Nature communications · 2023Article
- Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.Journal of medicinal chemistry · 2022Article
- The role of the gut microbiota in multiple sclerosis.Nature reviews. Neurology · 2022Review
- Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker.BMC genomic data · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
35 authors at 6 institutions in 3 countries.
Xiao-Chuan CaiChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States.
Tuo ZhangGenomics Resources Core Facility, Weill Cornell Medical College, Cornell University, New York, United States.
Eui-Jun KimMcArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, United States.
Ming JiangChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States.
Ke WangChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States.
Junyi WangChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States.
Shi ChenChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States.ORCID http://orcid.org/0000-0002-5860-2616
Nawei ZhangChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States.
Hong WuStructural Genomics Consortium, University of Toronto, Toronto, Canada.
Fengling LiStructural Genomics Consortium, University of Toronto, Toronto, Canada.
Carlo C Dela SeñaStructural Genomics Consortium, University of Toronto, Toronto, Canada.
Hong ZengStructural Genomics Consortium, University of Toronto, Toronto, Canada.
Victor VivcharukDepartment of Physiology and Biophysics, Weill Cornell Medical College of Cornell University, New York, United States.
Xiang NiuComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States.
Weihong ZhengChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States.
Jonghan P LeeChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States.
Yuling ChenCenter for Synthetic and Systematic Biology, School of Life Sciences, Tsinghua University, Beijing, China.
Dalia BarsyteStructural Genomics Consortium, University of Toronto, Toronto, Canada.
Magda SzewczykStructural Genomics Consortium, University of Toronto, Toronto, Canada.
Taraneh HajianStructural Genomics Consortium, University of Toronto, Toronto, Canada.
Glorymar IbáñezChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States.
Aiping DongStructural Genomics Consortium, University of Toronto, Toronto, Canada.
Ludmila DombrovskiStructural Genomics Consortium, University of Toronto, Toronto, Canada.
Zhenyu ZhangDepartment of Obstetrics and Gynecology, Chaoyang Hospital, Affiliation Hospital of Capital Medical University, Beijing, China.
Haiteng DengStructural Genomics Consortium, University of Toronto, Toronto, Canada.
Jinrong MinStructural Genomics Consortium, University of Toronto, Toronto, Canada.
Cheryl H ArrowsmithStructural Genomics Consortium, University of Toronto, Toronto, Canada.
Linas MazutisComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States.
Lei ShiDepartment of Physiology and Biophysics, Weill Cornell Medical College of Cornell University, New York, United States.
Masoud VedadiStructural Genomics Consortium, University of Toronto, Toronto, Canada.
Peter J BrownStructural Genomics Consortium, University of Toronto, Toronto, Canada.ORCID http://orcid.org/0000-0002-8454-0367
Jenny XiangGenomics Resources Core Facility, Weill Cornell Medical College, Cornell University, New York, United States.
Li-Xuan QinDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, United States.
Wei XuMcArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, United States.
Minkui LuoChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, United States.ORCID https://orcid.org/0000-0001-7409-7034
University of Toronto · CAMemorial Sloan Kettering Cancer Center · USCornell University · USUniversity of Wisconsin–Madison · USCapital Medical University · CNTsinghua University · CN
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MUser Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI MALCOLM S. CAPEL · 2018 to 2026
$34.2MInterrogating Protein Methyltransferases with Integrated ApproachesR35GM131858 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI Minkui Luo · 2019 to 2026
$6.3MProfile substrates and inhibitors of protein lysine methyltransferaseR01GM096056 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI LUO, MINKUI · 2011 to 2018
$3.2MProtein Arginine Methylation in Breast CancerR01CA236356 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Wei Xu · 2019 to 2026
$2.9MPixel Array Detector for Macromolecular CrystallographyS10OD021527 · OD · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2016 to 2016
$2.0MHigh-Speed High-Sensitivity Detector for X-ray Micro-Crystallography at GM/CA@APSS10OD012289 · OD · UNIVERSITY OF CHICAGO · PI FISCHETTI, ROBERT F. · 2014 to 2014
$2.0MInterrogating Functions of Protein Methyltransferases with Chemical ToolsR01GM120570 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI LUO, MINKUI · 2016 to 2019
$1.8MProtein Arginine Methylation in Chemotherapy ResistanceR01CA213293 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI XU, WEI · 2017 to 2021
$795kStatistical Evaluation and Selection of Normalization Methods for microRNA Sequencing Data in Cancer Biomarker StudiesR21CA214845 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI QIN, LI-XUAN · 2018 to 2019
$414kBeijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support YangFan Project - ZYLX201713Memorial Sloan Kettering Cancer Center Experimental Therapeutics CenterMemorial Sloan Kettering Cancer Center Functional Genomics InitiativeMemorial Sloan Kettering Cancer Center Metastasis and Tumor Ecosystems CenterNCI NIH HHS 5P30 CA008748NCI NIH HHS CA008748NCI NIH HHS CA214845NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA213293NCI NIH HHS R01CA213293NCI NIH HHS R01 CA236356NCI NIH HHS R01CA236356NCI NIH HHS R21 CA214845NIGMS NIH HHS P30 GM124165NIGMS NIH HHS R01 GM096056NIGMS NIH HHS R01 GM120570NIGMS NIH HHS R35 GM131858NIH HHS R01GM096056NIH HHS R01GM120570NIH HHS R35GM131858NIH HHS S10 OD012289NIH HHS S10 OD021527Special Funding of Beijing Municipal Administration of Hospitals Clinical Medicine Development YangFan Project ZYLX201713Starr Cancer Consortium I8-A8-058Susan G. Komen PDF17481306Susan G Komen Foundation PDF17481306Wellcome Trust
Abstract
CARM1 is a cancer-relevant protein arginine methyltransferase that regulates many aspects of transcription. Its pharmacological inhibition is a promising anti-cancer strategy. Here
Indexed as
AlgorithmsBreast NeoplasmsCell Line, TumorCrystallography, X-RayEnzyme InhibitorsEpigenesis, GeneticEpigenomicsFemaleHumansKineticsMCF-7 CellsModels, ChemicalMolecular StructureProtein-Arginine N-MethyltransferasesProtein Bindingcoactivator-associated arginine methyltransferase 1Enzyme InhibitorsProtein-Arginine N-Methyltransferasesbiochemistrychemical biologyepigenetichumaninhibitormechanismmethylationPRMTsingle cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.